Lornoxicam: A Review of its Pharmacology and Therapeutic Potential in the Management of Painful and Inflammatory Conditions

Drugs

Volumn 51, Issue 4, 1996, Pages 639-657

  Balfour, Julia A ^a   Fitton, Andrew ^a   Barradell, Lee B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DICLOFENAC; DIGOXIN; FUROSEMIDE; INDOMETACIN; KETOROLAC; LOOP DIURETIC AGENT; LORNOXICAM; METHOTREXATE; MORPHINE; THIAZIDE DIURETIC AGENT; TRAMADOL; WARFARIN;

AGE; ANALGESIC ACTIVITY; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DUODENUM ULCER; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; ISCHIALGIA; KIDNEY DISEASE; LIVER DYSFUNCTION; LOW BACK PAIN; MELENA; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; POSTOPERATIVE PAIN; REVIEW; RHEUMATOID ARTHRITIS; VOMITING;

ABSORPTION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DOSAGE FORMS; DRUG INTERACTIONS; HUMANS; LOW BACK PAIN; MIGRAINE DISORDERS; OSTEOARTHRITIS; PAIN; PAIN, POSTOPERATIVE; PIROXICAM; SPONDYLITIS, ANKYLOSING; TISSUE DISTRIBUTION;

EID: 0030000330     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651040-00008     Document Type: Review

References (76)

1. Pruss TP, Stroissnig H, Radhofer-Welte S, et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of Jornoxicam. Postgrad Med J 1990; 66 Suppl. 4: S18-21
2. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflammation Res 1995; 44: 1-10
3. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs - differences and similarities. N Engl J Med 1991; 324 (24): 1716-25
4. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994 Oct; 59: 9-43
5. Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut Lancet 1995; 346: 521-2
6. Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. TiPS 1994; 15: 405-6
7. Ferber HP, Maleschitz P, Binder D. Chlortenoxicam, a new NSAID, prevents the arachidonic acid-induced toxicity [abstract A387]. 2nd World Conference on Inflammation, Antirheumatics. Analgesics, Immunomodulators; 1986 Mar 19-22; Monte Carlo.
8. McCormack K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 1994; 47 Suppl. 5: 28-45
9. Kullich W, Klein G. Influence of the nonsteroidal anti-inflammatory drug lornoxicam i.v. on the secretion of the endogenous opiate peptides dynorphin and β-endorphin [in German]. Aktuel Rheumatol 1992 Jul; 17: 128-32
10. Nhrholt SE, Sindet-Pedersen S, Bugge C, et al. A randomized, double-blind, placebo-controlled, dose-response study of the analgesic effect of lornoxicam after surgical removal of mandibular third molars. J Clin Pharmacol 1995 Jun; 35: 606-14
11. Cooper SA, Beaver WT. A model to evaluate mild analgesics in oral surgery. Clin Pharmacol Ther 1976; 20: 241-50
12. Forbes JA. Oral surgery. In: Max M, Portenoy R, Laska E, editors. Advances in pain research and therapy. New York: Raven Press Ltd, 1991: 347-74
13. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989; 86: 449-58
14. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 36: 5-18
15. Weinstein M. Differentiation of nonsteroidal anti-inflammatory drug-associated and 'ordinary' peptic ulcers. In: Soll AH, moderator. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114: 307-19
16. Aabakken L. Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther. In press
17. Warrington SJ, Debbas NMG, Farthing M, et al. Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men. Postgrad Med J 1990 Aug; 66: 622-6
18. Kullich W, Klein G, Pollmann G. Influence of lornoxicam on serum pepsinogen levels. Postgrad Med J 1990; 66 Suppl. 4: S46-48
19. Girgis L, Brooks P. Nonsteroidal anti-inflammatory drugs: differential use in older patients. Drugs Aging 1994; 4: 101-12
20. Kenny GNC. Potential renal, haematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs 1992; 44 Suppl. 5: 31-7
21. Adams DH, Michael J, Bacon PA, et al. Non-steroidal anti-inflammatory drugs and renal failure. Lancet 1986; 1: 57-60
22. Warrington SJ, Lewis Y, Dawnay A, et al. Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation. Postgrad Med J 1990; 66 Suppl. 4: S35-40
23. Warrington SJ, Dawnay A, Johnston A, et al. Chlortenoxicam and renal function of normal human volunteers [letter]. Hum Toxicol 1989 Jan; 8: 53-4
24. Cunningham J, Wilkie M, Beer J, et al. The effect of renal dysfurction on the pharmacokinetic profile of lornoxicam. Hafslund Nycomed Pharma AG. (Data on file)
25. Merry P, Winyard PG, Morris CJ, et al. Oxygen free radicals, inflammation and synovitis: the current status. Ann Rheum Dis 1989; 48: 864-70
26. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet derived growth factor. Cell 1986; 46: 155-69
27. Dittrich P, Ferber HP, Kukovetz WR. Determination of chlortenoxicam, a novel nonsteroidal anti-inflammatory drug in human plasma [abstract P573]. 10th International Congress of Pharmacology: 1987 Aug 23-28; Sydney
28. Suwa T, Urano H, Shinohara Y, et al. Simultaneous high-performance liquid chromatographic determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection. J Chromatogr B Biomed Appl 1993 Jul; 617: 105-10
29. Dittrich P, Radhofer-Welte S, Magometschnigg D, et al. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drugs Exp Clin Res 1990; 16 (2): 57-62
30. Ankier SI, Brimelow AE, Crome P, et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med J 1988 Oct; 64: 752-4
31. Mayerhofer S, Welte S, Magometschnigg D, et al. The effect of food on pharmacokinetic parameters of the new NSAID lornoxicam in healthy volunteers [abstract]. 3rd Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunomodulators; 1989 Mar 15-18; Monte Carlo: 223
32. Dittrich P, Radhofer-Welte S, Mayerhofer S, et al. Comparative pharmacokinetics of parenteral lornoxicam [abstract]. Eur J Pharmacol 1990 Jul 6; 183: 2265-6
33. Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 1994; Feb; 26: 107-20
34. Hitzenberger G, Radhofer-Welte S, Takacs F, et al. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990; 66 Suppl. 4: S2-6
35. Albengres E, Urien S, Barre J, et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity. Int J Tissue React 1993; 15 (3): 125-34
36. 1B(CYP2C subfamily) in the actions of nonsteroidal antiinflammatory drugs. Drugs Exp Clin Res 1993; 19: 189-95
37. TB (CYP2C9) in the biotransformation of lornoxicam. Clin Pharmacol Ther 1995 Feb; 57: 152
38. Ravic M, Johnston A, Turner P, et al. The effect of repeated oral doses of lornoxicam on antipyrine elimination in normal human volunteers. Hum Exp Toxicol 1991 Oct; 10: 375-7
39. Turner P, Johnston A. Clinical pharmacokinetic studies with lornoxicam. Postgrad Med J 1990; 66 Suppl. 4: S28-29
40. Ravic M, Salas-Herrera I, Johnston A, et al. A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad Med J 1993 Nov; 69: 865-6
41. Ravic M, Salas-Herrera I, Johnston A, et at. Influence of lorroxicam a new non-steroidal anti-inflammatory drug on lithium pharmacokinetics. Hum Psychopharm 1993 Jul-Aug; 8: 289-92
42. Boobis SW. Alteration of plasma albumin in relation to decreased drug binding in uraemia. Clin Pharmacol Ther 1977; 22: 147-53
43. Reidenberg MM, Affrime M. Influence of disease on binding of drugs to plasma proteins. Ann N Y Acad Sci 1973; 226: 115-26
44. Wanwimolruk S, Birkett DJ, Brooks M. Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet 1982; 7: 85-92
45. Woodford-Williams E, Alvares AS, Webster D, et al. Serum protein patterns in normal and pathological aging. Gerontologia 1964; 10: 86-99
46. Wallace S, Whiting B, Runcie J. Factors affecting drug binding in plasma of elderly patients. Br J Clin Pharmacol 1976; 3: 327-30
47. Ilias W. Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol. Hafslund Nycomed Pharma AG. (Data on file)
48. Rosenow DE, van Krieken F, Stolke D, et al. Intravenous administration of lornoxicam, a new NSAID, and pethidine for postoperative pain. A placebo-controlled pilot study. Clin Drug Invest 1996; 11 (1): 11-9
49. Patel A, Skelly AM, Kohn H, et al. Double-blind placebo-controlled comparison of the analgesic effects of single doses of lornoxicam and aspirin in patients with post-operative dental pain. Br Dent J 1991 Apr 20; 170: 295-9
50. Hafslund Nycomed Pharma AG. A prospective single-centre, randomised, double-blinded, controlled phase III study with parallel groups in patients suffering from acute post-operative pain (discectomy/laminectomy) using morphine as the active control drug (2n = 96). Hafslund Nycomed Pharma AG. (Data on file)
51. Cooper SA, Hersh EV, Quinn PD, et al. Analgesic efficacy and safety of lornoxicam, a new oxicam derivative. Hafslund Nycomed Pharma AG. (Data on file)
52. Cooper SA, Lucyk D, Smith B, et al. An analgesic evaluation of lornoxicam [abstract]. 95th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1994 Mar 31-Apr 1; New Orleans: 126.
53. Hafslund Nycomed Pharma AG. A multicentre study using a randomised, bi-phase (double-blind/open-labelled) parallel group design in patients suffering from acute sciatica (3n = 90 for the confirmatory analysis). Hafslund Nycomed Pharma AG (Data on file)
54. Hafslund Nycomed Pharma AG. Multiple-dose study comparing the efficacy and safety of lornoxicam with placebo and diclofenac in patients with acute sciatica or lumbo-sciatica. Hafslund Nycomed Pharma AG (Data on file)
55. Rainer F, Klein G, Mayrhofer F, et al. A prospective, multicentre, open-label, uncontrolled Phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain. Eur J Clin Res 1996; 8: 1-13
56. Charlot J. Long term efficacy and tolerability of lornoxicam in elderly patients with rheumatoid arthritis or osteoarthritis: a multicenter, open study. Hafslund Nycomed Pharma AG. (Data on file)
57. Fernandez I. A multicentre, randomised, double-blind study comparing lornoxicam, a new NSAID, with naproxen in patients with chronic lower back pain. Hafslund Nycomed Pharma AG (Data on file)
58. Leeb B. Lornoxicam in the management of rheumatoid arthritis: a comparative study with piroxicam followed by long-term open-label treatment with lornoxicam. Hafslund Nycomed Pharma AG. (Data on file)
59. Hafslund Nycomed Pharma AG. Comparison of the efficacy and safety of lornoxicam and diclofenac in rheumatoid arthritis: a multicentre double-blind study followed by treatment with lornoxicam. Hafslund Nycomed Pharma AG. (Data on file)
60. Bernstein RM, Frenzel W. A comparative study of two dosage regimens of lornoxicam and a standard dosage of naproxen in patients with rheumatoid arthritis. Eur J Clin Res 1995; 7: 259-73
61. Berry H, Bird HA, Black C, et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis 1992 Feb; 51: 238-42
62. Hafslund Nycomed Pharma AG. Efficacy and safety of lornoxicam (8mg b.i.d) in comparison with placebo in patients with osteoarthritis of the knee - a four-week, randomized, prospective multicentre, double-blind, placebo-controlled, parallel group phase IIb study. Hafslund Nycomed Pharma AG. (Data on file)
63. Kidd B. A multicentre, randomised, double-blind study comparing lornoxicam with diclofenac in osteoarthritis. Hafslund Nycomed Pharma AG. (Data on file)
64. Caruso I, Montrone F, Boari L, et al. Lornoxicam versus diclofenac in rheumatoid arthritis: a double-blind, multicenter study. Adv Ther 1994 May-Jun; 11: 132-8
65. Bernstein RM, Calin HJ, Calin A. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm 1992; 12 (3): 6-13
66. Mayrhofer F, Siegmeth W, Kolarz G, et al. A multicentre, randomised, double-blind study comparing lornoxicam with diclofenac in patients with chronic lower back pain. Hafslund Nycomed Pharma AG. (Data on file)
67. Sternieri E, Bussone G, Manzoni GC, et al. Lornoxicam, a new non-steroidal anti-inflammatory drug, in migraine prophylaxis: a double-blind multicenter study. Cephalalgia 1991 Jun; 11 Suppl. 11: 154-5
68. Ravic M, Johnston A, Turner P, et al. Does bismuth chelate influence lornoxicam absorption? [letter]. Hum Exp Toxicol 1992 Jan; 11: 59-60
69. Ravic M, Johnston A, Turner P. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgrad Med J 1990; 66 Suppl. 4: S30-34
70. Ravic M, Johnston A, Turner P, et al. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 1990 Nov; 9: 413-4
71. Kramer HJ, Dusing R, Stinnesbeck B, et al. Interaction of conventional and antikaliuretic diuretics with the renal prostaglandin system. Clin Sci 1980; 59: 67-70
72. Hitoglou-Makedou A, Lawson M, Turner P, et al. Comparison of chlortenoxicam and indomethacin on furosemide-induced diuresis. Postgrad Med J 1989 Nov; 65: 821-3
73. Moote C. Efficacy of nonsteroidal anti-inflammatory drugs in the management of postoperative pain. Drugs 1992; 44 Suppl. 5: 14-30
74. Kehlet H, Dahl JB. Are perioperative nonsteroidal anti-inflammatory drugs ulcerogenic in the short term? Drugs 1992; 44 Suppl. 5: 38-41
75. Levy MH. Pharmacologic management of cancer pain. Semin Oncol 1994; 21: 718-39
76. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72